Literature DB >> 17606708

Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.

Peter T Campbell1, Laura Edwards, John R McLaughlin, Jane Green, H Banfield Younghusband, Michael O Woods.   

Abstract

PURPOSE: Lynch syndrome is a cancer predisposition syndrome which includes colon cancer. It is caused by inherited defects in DNA mismatch repair genes. Sporadic colon cancers are influenced by exogenous hormones (e.g., postmenopausal hormones); we hypothesized that polymorphisms which influence endogenous hormones would therefore modify age at colon cancer onset among Lynch syndrome mutation carriers. EXPERIMENTAL
DESIGN: We genotyped 146 Caucasian Lynch syndrome mutation carriers for a 5'-untranslated region polymorphism in cytochrome P450 17A1 (CYP17; c.-34T-->C) and an exon 4 polymorphism in catechol O-methyltransferase (COMT; c.472G-->A); 50 mutation carriers had developed colon or rectal cancer at last contact. We used chi(2) tests to assess differences in counts. Kaplan-Meier survival curves and Cox proportional hazard models assessed age at onset of colorectal cancer stratified by CYP17 and COMT genotypes.
RESULTS: Homozygous carriers of the CYP17 C allele were diagnosed with colorectal cancer 18 years earlier than homozygous carriers of the T allele. Hazard ratios identified that, relative to homozygous carriers of the T allele (T/T), carriers of one copy (T/C) and two copies (C/C) of the rare allele were, respectively, at 1.9-fold and 2.9-fold increased the risk of colon cancer at any age. The COMT rare allele suggested a nonstatistically significant trend of decreased colon cancer risk.
CONCLUSIONS: This study showed that a polymorphism in CYP17 (c.-34T-->C) modifies age at onset of Lynch syndrome. Because of the high risk of colorectal cancer among this group, knowledge of the CYP17 genotype is warranted for genetic counseling and risk assessment. Future work should assess polymorphisms associated with steroid hormones in Lynch syndrome mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606708     DOI: 10.1158/1078-0432.CCR-06-2987

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women.

Authors:  Michael N Passarelli; Polly A Newcomb; Karen W Makar; Andrea N Burnett-Hartman; Amanda I Phipps; Sean P David; Li Hsu; Tabitha A Harrison; Carolyn M Hutter; David J Duggan; Emily White; Andrew T Chan; Ulrike Peters
Journal:  Menopause       Date:  2014-04       Impact factor: 2.953

2.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

Authors:  Aung Ko Win; Joanne P Young; Noralane M Lindor; Katherine M Tucker; Dennis J Ahnen; Graeme P Young; Daniel D Buchanan; Mark Clendenning; Graham G Giles; Ingrid Winship; Finlay A Macrae; Jack Goldblatt; Melissa C Southey; Julie Arnold; Stephen N Thibodeau; Shanaka R Gunawardena; Bharati Bapat; John A Baron; Graham Casey; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; John L Hopper; Mark A Jenkins
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

3.  Chronic inflammation, colorectal cancer and gene polymorphisms.

Authors:  C Richard Boland
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

4.  Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene.

Authors:  Aung Ko Win; Jeanette C Reece; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; James G Dowty; Robert J MacInnis; Katherine M Tucker; Ingrid M Winship; Finlay A Macrae; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

5.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

6.  The association of low penetrance genetic risk modifiers with colorectal cancer in lynch syndrome patients: a systematic review and meta-analysis.

Authors:  Neil Donald; Salim Malik; Joshua L McGuire; Kevin J Monahan
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 7.  Genetic modifiers of cancer risk in Lynch syndrome: a review.

Authors:  Bente A Talseth-Palmer; Juul T Wijnen; Desma M Grice; Rodney J Scott
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.